Suppr超能文献

钙通道阻滞剂对抗肿瘤药物的增效作用及交叉耐药模式的特别参考

Potentiation of antitumor agents by calcium channel blockers with special reference to cross-resistance patterns.

作者信息

Tsuruo T, Kawabata H, Nagumo N, Iida H, Kitatani Y, Tsukagoshi S, Sakurai Y

出版信息

Cancer Chemother Pharmacol. 1985;15(1):16-9. doi: 10.1007/BF00257287.

Abstract

The calcium channel blockers verapamil, diltiazem, nicardipine, and niludipine potentiated the antitumor activities of mitotic poison antitumor agents, such as vincristine, vinblastine, vindesine, VP16-213, and taxol in P388 leukemia cells resistant to vincristine. The potentiating effect was generally dependent on the extent of cross-resistance seen in the cell line for these drugs. Calcium channel blockers also potentiate the antitumor activities of several DNA-interacting drugs, such as adriamycin, THP-adriamycin, daunomycin, aclacinomycin A, mitomycin C, actinomycin D, mitoxantrone, and nogalamycin derivatives in P388 leukemia resistant to adriamycin. Greater potentiation was observed for those antitumor agents to which the ADM-resistant cell line had become markedly cross-resistant, with the exception of the nogalamycin derivatives. Only a two-fold enhancement was observed for mitomycin C and aclacinomycin, as the cell line was only weakly cross-resistant to these agents. These results suggest the potential for therapeutic gain through the use of calcium channel blockers in combination with classic chemotherapeutic agents.

摘要

钙通道阻滞剂维拉帕米、地尔硫䓬、尼卡地平及尼鲁地平可增强有丝分裂毒性抗肿瘤药物(如长春新碱、长春碱、长春地辛、依托泊苷及紫杉醇)对长春新碱耐药的P388白血病细胞的抗肿瘤活性。这种增强作用通常取决于细胞系对这些药物的交叉耐药程度。钙通道阻滞剂还可增强几种与DNA相互作用药物(如阿霉素、吡柔比星、柔红霉素、阿克拉霉素A、丝裂霉素C、放线菌素D、米托蒽醌及诺加霉素衍生物)对阿霉素耐药的P388白血病细胞的抗肿瘤活性。除诺加霉素衍生物外,对阿霉素耐药细胞系已明显交叉耐药的那些抗肿瘤药物观察到更大的增强作用。丝裂霉素C和阿克拉霉素仅观察到两倍的增强,因为细胞系对这些药物仅有弱交叉耐药。这些结果提示,通过将钙通道阻滞剂与经典化疗药物联合使用有可能获得治疗益处。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验